COMMUNIQUÉS West-GlobeNewswire

STERIS Announces Financial Results for Fiscal 2025 Second Quarter
06/11/2024
Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7% As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14 Fiscal 2025 outlook [...]
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
06/11/2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06/11/2024
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in [...]
MacroGenics to Participate in Upcoming Investor Conferences
06/11/2024
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
06/11/2024
Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision [...]
Certara Reports Third Quarter 2024 Financial Results
06/11/2024
Updates Full Year 2024 Financial Guidance RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
06/11/2024
Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a [...]
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
06/11/2024
Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational [...]
Pennant Reports Third Quarter 2024 Results
06/11/2024
Conference Call and Webcast scheduled for tomorrow, November 7, 2024 at 10:00 am MT EAGLE, Idaho, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
TerrAscend Reports Third Quarter 2024 Financial Results
06/11/2024
Net Revenue of $74.2 million and Gross Profit Margin of 48.8% 9 th consecutive quarter of positive Cash Flow from continuing operations and fifth consecutive quarter of positive Free Cash Flow 1 Closed on a senior [...]
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
06/11/2024
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr [...]
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
06/11/2024
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - Duchenne: [...]
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
06/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class [...]
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
06/11/2024
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + [...]
Spectral AI Announces 2024 Third Quarter Financial Results
06/11/2024
Revenue Rose to $8.2 Million Company Reaffirms Timeline for Regulatory Submission to U.S. FDA Q3 2024 Overview Research & Development Revenue Rose 138% to $8.2 Million Last Patient Out at Burn Centers for U.S. Burn [...]
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
06/11/2024
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in [...]
OraSure Reports Q3 ’24 Revenue of $39.9 Million
06/11/2024
Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics [...]
PetMeds® Announces Second Quarter Fiscal 2025 Financial Results
06/11/2024
DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2024 [...]
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
06/11/2024
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and [...]

Pages